HMPL 004

Drug Profile

HMPL 004

Alternative Names: HM004-6599; HMPL-004

Latest Information Update: 14 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hutchison MediPharma
  • Developer Hutchison MediPharma; Nutrition Science Partners
  • Class Anti-inflammatories; Antiulcers
  • Mechanism of Action Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; NF-kappa B inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ulcerative colitis
  • Phase II Crohn's disease

Most Recent Events

  • 02 Aug 2016 Hutchinson MediPharma announces intention to submit IND application to FDA in 2017
  • 27 Jul 2015 Development is active in USA; Hutchison Medipharma and Nestle Health Science are discussing next steps for development of HMPL 004
  • 17 Jul 2013 Hutchison Medipharma and Nutrition Science Partners initiate enrolment in a phase III NATRUL-4 trial for Ulcerative colitis (treatment-resistant) in the USA (NCT01882764)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top